252873-01-1 Usage
Description
BIS THF Nitro Derivative 2, also known as (3S,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl 4-nitrophenyl ester carbonic acid, is an impurity found in bis-THF-derived compounds. These compounds are utilized as HIV-aspartyl protease inhibitors, playing a significant role in the development of antiretroviral drugs.
Uses
Used in Pharmaceutical Industry:
BIS THF Nitro Derivative 2 is used as an impurity in the development of [HIV-aspartyl protease inhibitors] for [their potential role in the treatment of HIV/AIDS]. The presence of this derivative in the synthesis process of these inhibitors may affect the overall efficacy and safety of the final drug product.
Used in Research and Development:
BIS THF Nitro Derivative 2 serves as a subject of study in the field of medicinal chemistry and drug development. Researchers investigate the properties, interactions, and potential effects of this compound on the overall performance of HIV-aspartyl protease inhibitors to improve their design and synthesis.
Used in Quality Control and Analysis:
In the manufacturing process of HIV-aspartyl protease inhibitors, BIS THF Nitro Derivative 2 is used as a reference compound for quality control and analytical purposes. Its identification and quantification in the final product help ensure the purity, safety, and efficacy of the antiretroviral drugs.
Check Digit Verification of cas no
The CAS Registry Mumber 252873-01-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,5,2,8,7 and 3 respectively; the second part has 2 digits, 0 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 252873-01:
(8*2)+(7*5)+(6*2)+(5*8)+(4*7)+(3*3)+(2*0)+(1*1)=141
141 % 10 = 1
So 252873-01-1 is a valid CAS Registry Number.
252873-01-1Relevant articles and documents
The Chiron Approach to (3 R,3 aS,6 aR)-Hexahydrofuro[2,3- b]furan-3-ol, a Key Subunit of HIV-1 Protease Inhibitor Drug, Darunavir
Ghosh, Arun K.,Markad, Shivaji B.,Robinson, William L.
, p. 1216 - 1222 (2020/12/22)
We describe an enantioselective synthesis of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-ol which is a key subunit of darunavir, a widely used HIV-1 protease inhibitor drug for the treatment of HIV/AIDS patients. The synthesis was achieved in optically pure form utilizing commercially available sugar derivatives as the starting material. The key steps involve a highly stereoselective substrate-controlled hydrogenation, a Lewis acid catalyzed anomeric reduction of a 1,2-O-isopropylidene-protected glycofuranoside, and a Baeyer-Villiger oxidation of a tetrahydrofuranyl-2-aldehyde derivative. This optically active ligand alcohol was converted to darunavir efficiently.
CRYSTALLINE DARUNAVIR
-
Page/Page column 10, (2013/08/15)
The present invention relates to a non-solvated crystalline Darunavir, process for its preparation and pharmaceutical composition comprising it. The present invention also relates to a process for the preparation of amorphous Darunavir from a non-solvated crystalline Darunavir.
Substrate envelope-designed potent HIV-1 protease inhibitors to avoid drug resistance
Nalam, Madhavi N.L.,Ali, Akbar,Reddy, G.S. Kiran Kumar,Cao, Hong,Anjum, Saima G.,Altman, Michael D.,Yilmaz, Nese Kurt,Tidor, Bruce,Rana, Tariq M.,Schiffer, Celia A.
, p. 1116 - 1124 (2013/10/01)
Summary The rapid evolution of HIV under selective drug pressure has led to multidrug resistant (MDR) strains that evade standard therapies. We designed highly potent HIV-1 protease inhibitors (PIs) using the substrate envelope model, which confines inhib
